본문 바로가기
KERD
논문KCI 등재

Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial

김지현|백광호|김병욱|김진일|Ji Hyun Kim|김준성|Sang Wook Kim|Su Jin Hong|Ki-Nam Shim|Hyun Joo Song
거트앤리버 소화기연관학회협의회|2016.07|Gut and Liver|제10권 제4호|pp. 556-561

2

조회

0

다운로드

8

인용

0

참고문헌

키워드

Drug resistanceHelicobacter pyloriDisease eradication

초록

Background/Aims: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. Methods: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. Results: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. Conclusions: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.

Abstract

Background/Aims: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. Methods: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. Results: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. Conclusions: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.

참고문헌 (36)

  1. Blaser MJ, "Helicobacter pylori and gastric diseases", BMJ, 316, pp.1507~1510 (1998)
  2. Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
  3. Wang J, "Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a metaanalysis", Digestion, 83, pp.253~260 (2011)
  4. Correa P, "Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and antihelicobacter pylori therapy", J Natl Cancer Inst, 92, pp.1881~1888 (2000)
  5. Malfertheiner P, "Helicobacter pylori eradication has the potential to prevent gastric cancer: a stateof-the-art critique", Am J Gastroenterol, 100, pp.2100~2115 (2005)
  6. Chan FK, "Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen", N Engl J Med, 344, pp.967~973 (2001)
  7. Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
  8. Coelho LG, "Latin-American Consensus Conference on Helicobacter pylori infection: Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE)", Am J Gastroenterol, 95, pp.2688~1691 (2000)
  9. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
  10. Lam SK, "Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection", J Gastroenterol Hepatol, 13, pp.1~12 (1998)
  11. Gisbert JP, "Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough", Aliment Pharmacol Ther, 34, pp.1255~1268 (2011)
  12. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
  13. Yim JY, "Seroprevalence of Helicobacter pylori in South Korea", Helicobacter, 12, pp.333~340 (2007)
  14. 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
  15. 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
  16. 허준, "한국에서 헬리코박터 파일로리에 대한 삼제요법의 치료율 변화", 대한소화기학회지, 63(3), pp.141~145 (2014), 대한소화기학회
  17. Zullo A, "High eradication rates of Helicobacter pylori with a new sequential treatment", Aliment Pharmacol Ther, 17, pp.719~726 (2003)
  18. Kim JS, "Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis", Clin Res Hepatol Gastroenterol, 38, pp.118~125 (2014)
  19. Gatta L, "Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children", Am J Gastroenterol, 104, pp.3069~3079 (2009)
  20. Jafri NS, "Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment", Ann Intern Med, 148, pp.923~931 (2008)
  21. Tong JL, "Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a metaanalysis", J Clin Pharm Ther, 34, pp.41~53 (2009)
  22. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
  23. 김준성, "Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis", Gut and Liver, 7(5), pp.546~551 (2013), 거트앤리버 발행위원회
  24. Graham DY, "Rational Helicobacter pylori therapy:evidence-based medicine rather than medicine-based evidence", Clin Gastroenterol Hepatol, 12(e3), pp.177~186 (2014)
  25. 안병락, "Antibiotic Resistance in Helicobacter pylori Strains and its Effect on H. pylori Eradication Rates in a Single Center in Korea", Annals of Laboratory Medicine, 33(6), pp.415~419 (2013), 대한진단검사의학회
  26. Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
  27. Gisbert JP, "Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients", J Clin Gastroenterol, 47, pp.130~135 (2013)
  28. Gisbert JP, "Second-line rescue therapy with levofloxacin after H. pylori treatment failure:a Spanish multicenter study of 300 patients", Am J Gastroenterol, 103, pp.71~76 (2008)
  29. Manfredi M, "Helicobacter pylori infection:sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate", Helicobacter, 17, pp.246~253 (2012)
  30. Zullo A, "Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice", J Gastrointestin Liver Dis, 19, pp.131~134 (2010)
  31. Kang KK, "Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea", World J Gastroenterol, 20, pp.6932~6938 (2014)
  32. Wu JY, "Evidence-based recommendations for successful Helicobacter pylori treatment", Expert Rev Gastroenterol Hepatol, 8, pp.21~28 (2014)
  33. Graham DY, "Letter: the ethics of using inferior regimens in H. pylori randomised trials", Aliment Pharmacol Ther, 35, pp.852~854 (2012)
  34. Yoon K, "Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea", J Gastroenterol Hepatol, 30, pp.490~495 (2015)
  35. Gatta L, "Global eradication rates for Helicobacter pylori infection: systematic review and metaanalysis of sequential therapy", BMJ, 347, pp.f4587~ (2013)
  36. 금보라, "프로톤 펌프 억제제 종류에 따른 Helicobacter pylori 제균 효과 비교-Omeprazole, Rabeprazole, Esomeprazole, Lansoprazole-", 대한소화기학회지, 46(6), pp.433~439 (2005), 대한소화기학회

관련 논문AI추천

Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis최황, 김병욱, 김윤경, 김준성, 이민영, 이보인, 지정선, 함주호거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제5호Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea대한상부위장관. 헬리코박터학회, Beom Jin Kim, Dong Ho Lee, Gwang Ha Kim, Gwang Ho Baik, Heung Up Kim, Hyuk Lee, Hyun-Soo Kim, Il Ju Choi, Jae Gyu Kim, Jae J. Kim, Jae Kyu Sung, Jayoun Kim, Jin Il Kim, Joongyup Lee, Ju Yup Lee, Moo In Park, Sang Gyun Kim, Sang Wook Kim, Seong Woo Jeon, Soon Man Yoon, Yong Chan Lee거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제5호The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea김나영, 김진욱, 서지연, 신철민, 이동호, 정광현, 정숙향, 조유리, 진은효, 황진혁거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제6호Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection김나영, 박영수, 송인성, 신철민, 이동호, 이승태, 임지현, 조현진거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제4호Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea김광하, 류동엽, 문지윤, 송근암, 송철수, 유현석, 이봉은, 정재훈, 정정임거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제4호Bismuth-Based Quadruple Therapy versus Metronidazole- Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial양영주, Baik Gwang Ho, Bang Chang Seok, Jang Hyun Joo, Kae Sea Hyub, Kim Hak Yang, Kim Jinseob, Lee Sang Pyo, Lim Hyun, Seo Seung In, Shin Woon Geon거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호

이 간행물의 다른 논문 (28건)

The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease PatientsKyeong Ok Kimpp. 487-488Is Elderly Age a Simple Predictive Factor for Inadequate Bowel Preparation before Colonoscopy?Hyun Gun Kimpp. 489-490Serum Procalcitonin Is a Candidate Biomarker to Differentiate Bacteremia from Disease Flares in Patients with Inflammatory Bowel DisSeong-Eun Kimpp. 491-492Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection김유선, Jung Hwa Minpp. 493-494Towards Steroid-Free Immunosuppression after Liver TransplantationShawn J. Pelletier, Victor M. Zaydfudimpp. 495-496
원문 보기